Psychedelic Frontiers Series – Part 3 | Psychedelic Healers: The Importance of Provider Involvement for Psychedelic Clinical Integration
In Psychedelic Frontiers: Diverse Perspectives on a Mental Health Revolution, FTI Consulting experts embark on a journey to explore the various ways in which psychedelic medicine is perceived across different stakeholder groups, including the research community, medical and mental health providers, and political stakeholders. The series aims to underscore the nuances of communicating about psychedelic medicines with vested parties, especially in regard to the therapeutic potential of these substances amid the growing mental health crisis. Our first installment explored the public perception of these substances, outlining how stigma and misinformation have hindered their therapeutic success, and our second installment delved into the perspectives of the scientific community in light of complex regulatory and public dynamics.
In this installment we explore the perspectives of the provider, who will ultimately be responsible for administering psychedelic therapies. The providers’ clinical perspective is key to enabling the broader acceptance of psychedelic therapies into mainstream medicine – but there are barriers that need to be overcome to successfully do so.
The integration of psychedelics into mainstream healthcare is gaining traction, marked by significant interest and cautious optimism amongst providers. Clinical perspectives on psychedelics’ safety, efficacy, and therapeutic potential are evolving, driven by both emerging research and anecdotal evidence from early adopters in the field.
Clinical Perspectives on Psychedelics
Recent studies indicate a growing consensus among providers regarding the therapeutic benefits of psychedelics. According to a 2023 study analyzing psychologists’ and psychotherapists’ perception of the integration of psychedelic therapeutics into their clinical practice, approximately 97% of surveyed providers support additional research into psychedelics, with 91% advocating for their medical use. The belief in psychedelics’ potential therapeutic benefits is strong, with 89% of providers recognizing their value in treating various mental health conditions. [1]
While providers are optimistic about the potential effectiveness of psychedelic-assisted therapies, they have also expressed concerns about their roles and how these new treatments fit into existing therapeutic frameworks. In the aforementioned survey, 33% expressed concerns surrounding safety and 27% are undecided over whether psychedelic use increases the risk of psychiatric disorders,[2] underscoring the need for rigorous, ongoing research and evidence-based guidelines for providers.
Engaging Providers
Psychologists and psychotherapists play a pivotal role in facilitating the adoption of alternative therapies. Most psychologists are willing to inform eligible patients about the potential benefits of psilocybin for mental health, with their experience and beliefs significantly influencing their openness to engage patients in such treatments.[3] Psychotherapists share this acceptance, indicating a broader acceptance within the mental health community.[4]
This acceptance is tamped down by concerns over the administration of psychedelic therapies, particularly the ideal location, preparation, and aftercare that should be administered to promote the greatest possible clinical benefits for participating patients. In addition, the need for proper informed consent is especially important for psychedelic therapies due to the substantial changes that can result from treatment, such as personality changes, perceptual changes, and altered metaphysical beliefs, all of which have the potential to exacerbate existing diagnoses.[5] These concerns are not insurmountable, but are evidence of the need for expanded clinician education regarding the integration of psychedelic therapies into clinical practice.
Medical students, although curious and optimistic about psychedelics, often lack knowledge about recent research. This gap points to the need for early education and awareness initiatives within medical training programs.[6] As the field of psychiatry prepares to embrace psychedelic-assisted therapies, integrating this knowledge into clinical training will be essential for future healthcare providers.
Takeaways
Education
Education is the key to developing clinician perspectives around psychedelic medicine. Through comprehensive educational campaigns tailored to priority constituencies, such as medical students and healthcare providers, long-held biases can be mitigated through evidence-based presentations on the latest research findings, safety protocols, and clinical applications of psychedelics.
In so doing, clinicians are not only better equipped to integrate psychedelic medicine into their practice, but are also prepared to answer any questions from patients on the topic – mitigating the continued spread of stigma from misinformed patients.
Engagement
Engaging with key stakeholders, including medical associations, regulatory bodies, and patient advocacy groups, is a crucial step in building consensus support for psychedelic research. This consensus support is a significant milestone towards eventual widespread clinical integration.
Support Networks
Establishing support networks, training resources, and opportunities to engage with fellow providers on the topic is essential to building momentum toward clinical use. Providers, in particular, have a powerful voice for advocacy. Their perspectives are frequently used by policymakers and other regulatory stakeholders to shape rule-making. This advocacy role not only makes clinicians influential but also underscores their importance in the process of clinical integration.
Related Insights
Related Expertise
[1] Aileen Kucsera, Trisha Suppes, Nancy A. Huang, “Psychologists’ and psychotherapists’ knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics,” Clinical Psychology & Psychotherapy (July 2, 2024)
[2] Id.
[3] Benjamin Hear, Michael Brubaker, George Richardson, “Counselors’ attitudes toward psychedelics and their use in therapy,” Journal of Counseling & Development (March 19, 2022)
https://onlinelibrary.wiley.com/doi/full/10.1002/jcad.12429
[4] Priel Meir, Leslie Taylor, Jair C. Soares, Thomas D. Meyer, “Psychotherapists’ openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment,” Journal of Affective Disorders (February 15, 2023)
https://www.sciencedirect.com/science/article/abs/pii/S0165032722014100
[5] Mason Marks, Rebecca W. Brendel, Carmel Shachar, et al, “Essentials of Informed Consent to Psychedelic Medicine,” JAMA Psychiatry (April 10, 2024), https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2817593
[6] Irene Li, Rodney Fong, Molly Hagen, Burton Tabaac, “Medical student attitudes and perceptions of psychedelic-assisted therapies,” Frontiers in Psychology (June 27, 2024)
The views expressed in this article are those of the author(s) and not necessarily the views of FTI Consulting, its management, its subsidiaries, its affiliates, or its other professionals. FTI Consulting, Inc., including its subsidiaries and affiliates, is a consulting firm and is not a certified public accounting firm or a law firm. FTI Consulting is an independent global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. FTI Consulting professionals, located in all major business centers throughout the world, work closely with clients to anticipate, illuminate and overcome complex business challenges and opportunities. ©2024 FTI Consulting, Inc. All rights reserved. www.fticonsulting.com |
